Breast cancer is the most common type, accounting for 26% of all female cancers in the United States. In 2007, approximately 178,480 women and 2030 men will be diagnosed with invasive breast cancer and 40,460 women and 480 men will die from the disease.
Recently, our understanding of breast cancer biology is increasing by the findings that the breast cancer represents a family of tumours, sharing the same origin organ, with specific molecular features and prognostic implications. In this regard, molecular markers as hormonal receptors (HRs) and HER2/neu are the most important tools for therapeutic decision, albeit genomic profiling, performed with tissue chip microarrays, are a very interesting and promising approach.
During the last three decades, since Judah Folkman hypothesis in early 1970s, 1 accumulating data concerning tumour biology suggest that angiogenesis is a crucial step in the growth, invasion and metastatic dissemination in cancer. Now it is increasingly clear that the cancer cell is only partially responsible for tumour progression and that the tumour microenvironment, formed by endothelial and bone marrow derived cells, has a crucial role in disease development. Therefore, acting on these cells can augment the efficacy of cancer cell targeted therapy as chemotherapeutic agents and molecular targeted drugs.
The angiogenesis is an important developmental mechanism implicated in many physiological and pathological processes. Amongst the many factors implicated in angiogenesis most attention is catalysed, during these years, by VEGF (vascular endothelial growth factor) system. VEGF-A (commonly referred as VEGF), the major proangiogenic factor, circulating as various isoforms (VEGF121 and VEGF165), belong to the VEGF family of growth factors, comprising VEGF-A (referred as VEGF), VEGF-B, VEGF-C, VEGF-D VEGF-E and PlGF. 2, 3 VEGF production is finely regulated by various stimuli as hypoxia (via hypoxia-inducible factor 1a, HIF-1a), 4 and tumour suppressor genes, nitric oxide, and EGFR family receptors (EGFR and HER2). 5 VEGF activity is mediated by binding on cell surface expressed tyrosine-kinase receptors, called VEGFR-1 (flt-1), VEG-FR-2 (flk-1/KDR) and VEGFR-3 (flt-4) and Neuropilin1-2. 6 Although VEGFR-2 is classically defined as the principal mediator of VEGF transduction activity, increasing evidence suggests a central role in many processes also for VEGFR-1.
VEGF promotes the growth of structurally chaotic and functional aberrant vessels into tumour burden, 7 increases permeability, raising intratumoural pressure that, in turn, prevents the penetration of chemotherapeutic agents into the tumour, 8 and prevents the apoptosis of immature pericyte on vessels critical for the tumour. 9 All these features, added to the limited role that VEGF plays in healthy adults, explain why its targeting is strongly pursued for therapeutic purposes.
The importance of VEGF in breast cancer was first proved in preclinical and in clinical setting.
In the preclinical models VEGF expressing breast cancer cells demonstrated increased growth and metastatic potential in human tumour xenografts. 10 In the clinical setting VEGF overexpression in the early stage breast cancer was related to worse distant Disease-free survival, accounting for a major metastatic potential, and with the resistance to systemic chemotherapy and hormonal therapy. [11] [12] [13] [14] Moreover, HER2 overexpression in breast cancer is associated with VEGF overexpression. [15] [16] [17] Recent preclinical studies show that VEGFR-2 is overexpressed on some breast cancer cells and that VEGF can act as an autocrine loop on this tumour cells, associated with a paracrine loop involving cancer and endothelial cells. This observation, albeit very interesting, has not been yet confirmed in clinical setting, though many reports show the presence of either VEGFR1 and/or -2 on breast cancer cell surface. 18, 19 The first VEGF antagonist was a monoclonal antibody approved by FDA for the treatment of metastatic colorectal patients in February 2004 and, after few months, worldwide with the same indication: bevacizumab (Avastin Ò ).
Parallel to colorectal cancer, bevacizumab demonstrated activity in many type of cancer such as renal cell cancer (RCC), non-small cell lung cancer (NSCLC) and breast cancer.
In this regard, bevacizumab was approved by EMEA on the 27th March 2007 for the treatment of previously untreated metastatic breast cancer patients.
Bevacizumab is a humanised (93% human and 7% murine) monoclonal antibody designed to efficiently recognise and bind all the major isoforms of circulating VEGF. With a terminal half-life of 17-21 d it can be associated with the most common chemotherapeutic administration schedules. 20 
Preclinical data with bevacizumab
In human breast cancer xenograft models either the A4.6.1, the murine precursor of bevacizumab or bevacizumab has demonstrated a certain activity in inhibiting angiogenesis and tumour growth and spreading, given alone or in combination with chemotherapeutics and other targeted agents (trastuzumab). 21-23
Clinical data with bevacizumab: focus on mBC
On the basis of preclinical data some early clinical studies were conducted in humans to assess the feasibility of bevacizumab administration. Following phase I studies some phase I/II studies were performed in breast cancer patients to define the optimal dose and obtain an early assessment of the drug activity in this setting.
Cobleigh and colleague conducted a phase I/II trial in 75 pretreated mBC patients to primarily assess the overall response rate and the safety of three different doses of bevacizumab (3, 10, 20 mg/kg every 2 weeks) administered alone. At the dose of 10 mg/kg, there was one CR and four PR versus zero and one, respectively, for the 20 mg/kg dose. Although the overall response rate (ORR) was very low, this study showed a median duration of response of 5.6 months and provided better data for the antiangiogenic drug alone than was observed in the early phase II studies with capecitabine. 24 The safety profile was favourable with hypertension G3 in 17% of patients treated with the intermediate dose comparing with 22% and 19% of patients treated with 3 mg/kg and 20 mg/kg, respectively. Based on these data 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks was selected as the dose for the further phases II and III studies.
These data support the investigation of bevacizumab combined with chemotherapy. The first phase III study was designed and performed. In this study, 462 pretreated mBC patients were randomised to receive capecitabine plus bevacizumab or capecitabine alone. The progression free survival (PFS) was the primary end-point and there was no statistically significant difference between the two groups of patients (4.2 versus 4.9 for those treated with capecitabine + bevacizumab). Similarly, also median overall survival (OS), 14.5 versus 15.1 for capecitabine versus capecitabine + bevacizumab, respectively, was not reached a statistical difference. The ORR (assessed by an independent review facility) was higher for the combination treatment arm: 19.8 months versus 9.1 months (p 0.001). 25 The key explanation of the failure to achieve PFS and OS advantages for this study was that VEGF is expressed throughout the tumour lifecycle, but other factors (i.e. bFGF, TGF-b, PlGF and pleiotrophin) come into play at later stages. Thus tumours may escape anti-VEGF treatment by using alternative pro-angiogenic pathways. A direct consequence of this theory is that VEGF-driven angiogenesis plays a more important role in early stage of tumour formation, thus the anti-VEGF treatments should be administrated early in cancer therapy.
A more recent phase III trial evaluated weekly paclitaxel alone or in combination with bevacizumab, given at the dose of 10 mg/kg every 2 weeks, as first-line treatment in locally advanced mBC patients. The trial was early stopped due a scheduled interim analysis by an independent data monitoring committee which concluded that was met the PFS, primary end-point of the study. Indeed at the date of the interim analysis PFS was 5.8 months for patients who received paclitaxel alone and 11.4 months for those who received combination therapy (p < 0.0001). In addition, the ORR was increased from 23.4% for paclitaxel arm to 48% for combination arm (p < 0.0001). This meaningful increase in PFS and ORR was observed in all pre-specified subgroups of patients. Although the increased trend for OS observed for patients who received combination therapy was not significantly different compared to those receiving paclitaxel alone (26.6 versus 24.8, respectively; p 0.14), an exploratory analysis reported that the addition of bevacizumab to paclitaxel led to higher 1 year OS (82.3 versus 72.8%, p 0.007). 26 To explain the lack in survival advantage it may be argued that in the study analysis were not considered the different subsequent therapies that may affect the results of first-line therapy.
However, the magnitude of the PFS and ORR data, higher than other ever observed in first-line mBC treatment, led to EMEA and FDA approval of the combination of bevacizumab with paclitaxel in first-line mBC patients.
Other studies assessing efficacy and feasibility of the combination of bevacizumab with other targeted and conventional agents were performed in these years or are ongoing. [27] [28] [29] [30] [31] In particular the combination of bevacizumab and docetaxel, another drug widely used in mBC treatment, was investigated by some phase II and III studies with some successes. 27, 28 A phase III study, known as AVADO, randomised 736 patients until March 2007 to receive docetaxel plus placebo or bevacizumab every 3 weeks at the dose of 7.5 mg/kg or 15 mg/kg in combination with docetaxel. The AVADO trial demonstrated a higher ORR, Time to Treatment Failure and PFS in the bevacizumab 7.5 mg/kg and 15 mg/kg as compared to placebo arm.
Other ongoing two phase III studies, RIBBON1 and 2 are evaluating the role of bevacizumab combination with some chemotherapy regimens. In particular, RIBBON1 study will evaluate the safety and the efficacy of the bevacizumab combined with anthracycline-based, capecitabine and taxane as first-line therapy for mBC patients. The RIBBON2 study is designed to assess the efficacy of bevacizumab when associated with standard non-anthracycline-based chemotherapy in previously treated mBC patients.
After the approval by major regulatory agencies (i.e. FDA and EMEA) of the first-line combination of bevacizumab and paclitaxel, a large phase IV started assessing the safety profile of this treatment in locally recurrent mBC patients (MO19391).
Based on the abovementioned evidence of HER2 and VEGF co-expression on breast cancer cell surface and the crosstalk between HER2 pathway and VEGF, 23 a phase I/II study was performed with bevacizumab associated to trastuzumab in HER2 positive mBC patients. Early results on 37 patients suggest that the combination is well tolerated with only few G3/ G4 events reported. Preliminary efficacy data showed 19 PR and one CR with 11 patients with stable disease. 32, 33 These interesting data represent the basis on which was designed and has been started a phase III study (AVEREL) investigating the efficacy of bevacizumab addition to first-line trastuzumab and docetaxel therapy for HER2 mBC patients (n = 412).
Neoadjuvant and adjuvant
Ongoing trials are now evaluating the role of bevacizumab in neoadjuvant and adjuvant setting. In neoadjuvant setting, the phase III ongoing trial is investigating the role of adding bevacizumab to sequential combi-natorial therapy with 3 · 2 arms of treatment: docetaxel +/bevacizumab or docetaxel + capecitabine +/-bevacizumab or docetaxel + gemcitabine +/-bevacizumab followed by two arms epirubicin + cyclophosphamide (AC) +/-bevacizumab. The primary end-point is the pathological complete response rate (CRR), the secondary end-points are ORR, DFS and safety.
In adjuvant setting three sets of trials are ongoing for triple negative breast cancer patients, HER2 negative and HER2 positive breast cancer patients.
In HER2 negative group two studies are investigating different integration schedules of bevacizumab in adjuvant therapy. The E2104 study is designed to provide the 'proof of concept' that bevacizumab is feasible with an anthracyclinebased therapy in adjuvant setting. E2104 is a two step phase II trial in which node-positive patients receive chemotherapy with doxorubicin plus cyclophosphamide followed by paclitaxel and receive bevacizumab beginning into the doxorubicin/cyclophosphamide phase of treatment or in the paclitaxel phase, in this case the subsequential maintenance with bevacizumab alone is for 22 cycles instead of 18.
The second study (E5103) is designed to primarily evaluate the efficacy in DFS prolongation of adding bevacizumab to sequential schedule with AC followed by paclitaxel in nodepositive or high risk node-negative, HER2-negative, resected BC patients. Secondary end-points of this study are to comparing the OS of the patients treated with this regimen, to evaluate the toxicity profile of the combination therapy and to compare the impact of short-term (20-24 weeks) versus long-term (50-54 weeks) administration of bevacizumab on the DFS for this patient.
Based on the cooperative effect showed in the phase II study performed by Pegram et al. between trastuzumab and bevacizumab in mBC patients BETH study is evaluating the efficacy of this combination the adjuvant setting for HER2-positive fully resected BC patients.
BEATRICE study will evaluate bevacizumab therapy in association with standard chemotherapy regimens as adjuvant treatment in triple negative BC patients comparing standard chemotherapy alone. The primary end-point is invasive-DFS, and secondary end-points are OS, DFS, distant-DFS, tolerability and safety of the combination.
Breast cancer is often an hormone-dependent disease in early phases. Hormones can play a role in angiogenesis, too. In particular, regulatory regions of the VEGF gene contain elements responsive to oestrogen, 34 estrogens increase VEGF levels in breast cancer cell lines. 35 For all these reasons many ongoing studies are investigating the role of bevacizumab in association with hormonal therapy. The first, GEICAM 2006-11, is evaluating the efficacy and safety of combination of letrozole plus bevacizumab versus letrozole alone in previously untreated HR positive mBC patients suitable for a first-line hormonal treatment. In the second, the double-blinded study CAL-GB40503 was evaluated the efficacy of the bevacizumab combined with AI or tamoxifen versus AI or tamoxifen alone.
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